Our conclusions raise an important question that has been ignored during the development of Hsp90 inhibitors but can affect both the mechanism of drug action and the anticancer activity of drugs markedly: are Hsp90 inhibitors capable of inactivating all Hsp90 family proteins within different cellular compartments of cancer cells? Here, HSP90AA1 is linked to cancer.